Conjustar announced the completion of ￥100 million Pre-A+ round of financing. This round of financing was led by Fosun health Capital New Drug Innovation Fund of Fosun Pharmaceutical, and co-invested by Hengqin Venture Capital and Shenzhen Qianhai Liyuan.
On August 8, 2024, Conjustar Biologics announced that the investigational new drug (IND) application for the company's second peptide-drug conjugate (PDC), SC-102 for Injection, for the treatment of advanced malignant solid tumors expressing EphA2, was approved by the Center for Drug Evaluation (CDE) of the Chinese National Medical Products Administration.
